HopeStage
Back to all studies
TerminatedNCT01842542

Efficacy and Safety Study of NeuroStar TMS Therapy in Patients With Major Depressive Disorder With Postpartum Onset

Device studyAges 18–50United StatesDepression
The study in practice

Understand this study

Who could participate?

This study is for people with depression. Listed age limits: 18 years to 50 years. Other eligibility criteria apply.

Listed locations
Hartford and 7 more locationsSee all locations and recruitment

Get this study by email

HopeStage may email me about this study.
Loading the security check...

What to know before participating

A point to clarify

This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?

Study clarity

Things to check before joining

Study start dateStarted: December 2013
Recruitment status
Terminated
Enrollment listed in the registry
25
Sponsor
Neuronetics
Sponsor type
Unknown or unclear
Study type
Device
Intervention type
Device
Locations
United States
Age range
From 18 Years to 50 Years
Official registry ID
NCT01842542
Official title
Show the full official title

An Open-Label Study to Evaluate the Efficacy and Safety of the Neuronetics NeuroStar TMS Therapy System in Patients With Major Depressive Disorder (MDD) With Postpartum Onset.

Recruitment & locations

Terminated

Hartford · Gainesville · Pensacola

5 more locations
  • Chicago
  • Louisville
  • New York
  • Allentown
  • Salt Lake City

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Neuronetics.

Who can participate?

This study is for people with depression. Listed age limits: 18 years to 50 years. Other eligibility criteria apply.

Is this study still recruiting?

The registry lists this study as terminated.

Want to explore more studies?

Explore studies